Trial results

$RGNX — sura-vec

REGENXBIO Inc. (RGNX) sura-vec: trial results in Wet age-related macular degeneration (wet AMD), 2026.

Research by Catalyst Intel

The catalyst

"Topline data from these trials are expected to be announced in the fourth quarter of 2026 in partnership with AbbVie, with global regulatory submissions expected in 2027."

— REGENXBIO Inc., 10-Q filed 2026-11-05 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

RGNX-SURAVEC-2026

Company

REGENXBIO Inc.

Kind

Trial results

Indication

Wet age-related macular degeneration (wet AMD)

Window

2026-10-01 – 2026-12-31

Status

dropped

The bar

No bar has been published for this event yet.

Verdicts

No verdict has been published for this event yet.